Bio-Rad Laboratories, Inc. (BIO) Stake Held by Franklin Resources Inc.

Franklin Resources Inc. maintained its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 107,628 shares of the medical research company’s stock at the end of the second quarter. Franklin Resources Inc. owned approximately 0.36% of Bio-Rad Laboratories worth $24,357,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Bio-Rad Laboratories by 9,953.4% in the first quarter. BlackRock Inc. now owns 1,733,111 shares of the medical research company’s stock worth $345,478,000 after buying an additional 1,715,872 shares in the last quarter. Vanguard Group Inc. raised its stake in Bio-Rad Laboratories by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,673,274 shares of the medical research company’s stock worth $333,550,000 after buying an additional 58,774 shares in the last quarter. TimesSquare Capital Management LLC raised its stake in Bio-Rad Laboratories by 1.6% in the second quarter. TimesSquare Capital Management LLC now owns 621,650 shares of the medical research company’s stock worth $140,686,000 after buying an additional 9,950 shares in the last quarter. Alliancebernstein L.P. raised its stake in Bio-Rad Laboratories by 1.7% in the first quarter. Alliancebernstein L.P. now owns 335,197 shares of the medical research company’s stock worth $66,818,000 after buying an additional 5,647 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in Bio-Rad Laboratories by 1.9% in the second quarter. Fisher Asset Management LLC now owns 279,589 shares of the medical research company’s stock worth $63,274,000 after buying an additional 5,233 shares in the last quarter. 62.84% of the stock is owned by institutional investors.

A number of research firms recently issued reports on BIO. Deutsche Bank AG reissued a “buy” rating and issued a $255.00 price target on shares of Bio-Rad Laboratories in a research note on Monday. TheStreet downgraded shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, August 3rd. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research note on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price target for the company. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $275.00 price target on shares of Bio-Rad Laboratories in a research note on Friday, July 14th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $240.80.

In related news, EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the sale, the executive vice president now owns 2,060 shares in the company, valued at approximately $444,774.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 28.29% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Bio-Rad Laboratories, Inc. (BIO) Stake Held by Franklin Resources Inc.” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2017/09/20/bio-rad-laboratories-inc-bio-stake-held-by-franklin-resources-inc.html.

Bio-Rad Laboratories, Inc. (NYSE BIO) opened at 230.35 on Wednesday. The company has a market capitalization of $6.83 billion, a P/E ratio of 455.24 and a beta of 0.93. The company has a 50-day moving average of $220.74 and a 200-day moving average of $217.89. Bio-Rad Laboratories, Inc. has a 1-year low of $154.89 and a 1-year high of $242.79.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply